Skip to main content

Research Repository

Advanced Search

Prednisolone-induced diabetes mellitus in the cat: a historical cohort

Nerhagen, S; Moberg, HL; Boge, GS; Glanemann, B


S Nerhagen

HL Moberg

GS Boge

B Glanemann


Prednisolone is a commonly used drug in cats and potential adverse effects include hyperglycaemia and diabetes mellitus. The aims of this study were to evaluate the frequency and investigate potential predisposing risk factors for the development of prednisolone-induced diabetes mellitus (PIDM) in cats.

The electronic records of a tertiary referral centre were searched for cats receiving prednisolone at a starting dose of ⩾1.9 mg/kg/day, for >3 weeks and with follow-up data available for >3 months between January 2007 and July 2019. One hundred and forty-three cats were included in the study.

Of the 143 cats, 14 cats (9.7%) were diagnosed with PIDM. Twelve out of 14 cats (85.7%) developed diabetes within 3 months of the initiation of therapy.

Conclusions and relevance
Cats requiring high-dose prednisolone therapy should be closely monitored over the first 3 months of therapy for the development of PIDM.


Nerhagen, S., Moberg, H., Boge, G., & Glanemann, B. (2020). Prednisolone-induced diabetes mellitus in the cat: a historical cohort. Journal of Feline Medicine and Surgery, 1098612X2094352.

Journal Article Type Article
Acceptance Date Jun 18, 2020
Publication Date Jul 27, 2020
Deposit Date Aug 18, 2020
Publicly Available Date Aug 18, 2020
Journal Journal of Feline Medicine and Surgery
Print ISSN 1098-612X
Publisher Elsevier
Peer Reviewed Peer Reviewed
Pages 1098612X2094352
Public URL
Publisher URL


You might also like

Downloadable Citations